Redmile Group LLC lowered its stake in Cabaletta Bio, Inc. (NASDAQ:CABA – Free Report) by 67.8% in the 1st quarter, HoldingsChannel.com reports. The firm owned 442,826 shares of the company’s stock after selling 931,363 shares during the quarter. Redmile Group LLC’s holdings in Cabaletta Bio were worth $7,555,000 at the end of the most recent reporting period.
Other institutional investors have also recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD boosted its stake in shares of Cabaletta Bio by 16.0% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 612,398 shares of the company’s stock worth $10,448,000 after acquiring an additional 84,633 shares in the last quarter. Westwood Holdings Group Inc. acquired a new position in shares of Cabaletta Bio in the first quarter worth $1,403,000. EntryPoint Capital LLC purchased a new stake in shares of Cabaletta Bio during the 1st quarter worth about $147,000. Vanguard Group Inc. lifted its stake in Cabaletta Bio by 6.8% in the first quarter. Vanguard Group Inc. now owns 2,276,222 shares of the company’s stock valued at $38,832,000 after acquiring an additional 144,291 shares during the last quarter. Finally, Blair William & Co. IL increased its stake in shares of Cabaletta Bio by 47.3% during the 1st quarter. Blair William & Co. IL now owns 27,300 shares of the company’s stock worth $466,000 after purchasing an additional 8,762 shares during the last quarter.
Wall Street Analyst Weigh In
A number of research analysts have recently commented on the company. HC Wainwright reissued a “buy” rating and set a $30.00 price objective on shares of Cabaletta Bio in a report on Friday, June 14th. Citigroup raised their target price on Cabaletta Bio from $26.00 to $30.00 and gave the company a “buy” rating in a report on Thursday, April 4th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $50.00 price objective on shares of Cabaletta Bio in a research report on Friday, June 21st. Finally, Stifel Nicolaus reiterated a “buy” rating and issued a $32.00 price objective on shares of Cabaletta Bio in a research report on Monday, June 17th. Nine equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and an average price target of $34.44.
Cabaletta Bio Stock Performance
Shares of NASDAQ:CABA traded down $0.11 on Monday, hitting $7.08. The stock had a trading volume of 462,954 shares, compared to its average volume of 1,111,095. The company has a market capitalization of $341.80 million, a price-to-earnings ratio of -4.14 and a beta of 2.42. The firm’s 50 day moving average price is $8.90 and its 200-day moving average price is $15.06. Cabaletta Bio, Inc. has a twelve month low of $6.71 and a twelve month high of $26.35.
Cabaletta Bio (NASDAQ:CABA – Get Free Report) last posted its earnings results on Wednesday, May 15th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.03). As a group, sell-side analysts predict that Cabaletta Bio, Inc. will post -2.07 EPS for the current year.
Cabaletta Bio Company Profile
Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis.
Recommended Stories
- Five stocks we like better than Cabaletta Bio
- What Are Dividend Champions? How to Invest in the Champions
- Survey: Top 175 Fittest Retirement Locations in America
- Where Do I Find 52-Week Highs and Lows?
- Kimberly-Clark Stock Dips and a Buying Opportunity Emerges
- What to Know About Investing in Penny Stocks
- Leading Gold Stock Shines With Q2 2024 Earnings Release
Want to see what other hedge funds are holding CABA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cabaletta Bio, Inc. (NASDAQ:CABA – Free Report).
Receive News & Ratings for Cabaletta Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cabaletta Bio and related companies with MarketBeat.com's FREE daily email newsletter.